A
Arteaus Therapeutics
A biotechnology development company creating new therapies to treat migraine.
About Arteaus Therapeutics
Arteaus Therapeutics, LLC operated as a specialized biotechnology development company with a clear, asset-centric focus on creating a new therapy for migraine prevention. Founded in 2011 by Scott Chappell, with David Grayzel, MD, serving as CEO, the company was established through a strategic collaboration with Eli Lilly and Company. This venture was a prime example of a "built-to-buy" model, initiated by Atlas Venture Development Corp (AVDC), a unit of Atlas Venture, alongside OrbiMed.
The company's formation was centered on a single asset: a calcitonin gene-related peptide (CGRP) antibody, LY2951742, which was originally discovered by scientists at Eli Lilly. Arteaus was launched with an $18 million Series A investment from Atlas Venture and OrbiMed to exclusively license and advance this antibody through clinical development. The business model was designed to be capital-efficient, utilizing a virtual team to take the drug through to a key value inflection point—specifically, a Phase 2 proof-of-concept study. This approach enabled a larger pharmaceutical company to externalize a portion of its R&D, leveraging the entrepreneurial and focused structure of a small biotech firm.
Arteaus' sole product was the antibody LY2951742 (now known as galcanezumab or Emgality), designed to prevent migraine headaches. This therapeutic antibody works by targeting and blocking CGRP, a sensory neuropeptide implicated in the vascular and inflammatory processes that contribute to migraines. The intended benefit for patients suffering from frequent migraines was a reduction in the frequency of attacks through a self-administered, once-monthly injection. After successfully completing the Phase 2 trial within approximately 2.5 years, demonstrating the drug's potential efficacy and safety, Eli Lilly exercised its option to reacquire the full development rights in January 2014 for approximately $57.1 million. Following the acquisition, Arteaus Therapeutics was wound down, having fulfilled its specific mission. The investors later sold their royalty interests on the drug's sales to Royalty Pharma in 2019 for $260 million.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jul 2012 | $12M | $48M | Atlas Venture · OrbiMed | — |
| EARLY VC✓Equity / VC | Oct 2011 | $18M | $72M | Atlas Venture · OrbiMed | — |
Growth signals
Latest recorded traffic for Arteaus Therapeutics is 230 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Arteaus Therapeutics in the Cambridge ecosystem
The Arteaus Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Arteaus Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Arteaus Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.











